Imbria Pharmaceuticals Raises $57.5M in Series B Financing
Summary
Its clinical pipeline is focused on restoring or improving the cells ability to produce energy in cardiometabolic disorders where energetic impairment is a fundamental contributor to disease pathogenesis, symptoms and functional deficits. The lead product candidate, ninerafaxstat, has completed multiple Phase 2 clinical trials in three indications: non-obstructive hypertrophic cardiomyopathy (nHCM), stable angina, and heart failure with preserved ejection fraction (HFpEF). In Phase 1 and 2 clinical trials, ninerafaxstat was shown to be well tolerated.The company intends to use the proceeds to advance ninerafaxstat through a Phase 2b randomized, double-blind, placebo-controlled, clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM), called FORTITUDE-HCM, and to initiate FORTITUDE-HCM in Q2 2025, with topline data in late 2026.The company also announced the appointment of its current Executive Chair, Alvin Shih, MD to the Chief Executive Officer role, plus the appointment of Rebecca Luse, Managing Director at Deep Track Capital, to its Board of Directors. To maintain normal contractile function, the heart requires substantial amounts of energy, which is produced primarily by the mitochondria in the form of adenosine triphosphate (ATP). Ninerafaxstat is a simple orally administered compound with no dose titration or monitoring required, no clinically significant drug-drug interactions and can be used on top of standard of care cardiovascular treatments.